ADCs are a growing and complex class of therapeutics that present unique challenges but offer incredible patient benefits. Bioconjugation is a critical element in developing ADCs and other targeting and delivery agents. Join this event hosted by Innovation District Copenhagen-partner SYMBION to meet integrated drug substance to drug product strategic partner Lonza and learn how they might support your start-up through de-risking and development to clinical manufacture.
WHAT
Scientific seminar about molecule design in the ADC, monoclonal antibody, bispecific, or small molecule space especially in the oncology field. Speaker: drug product strategic partner Lonza. Learn more and sign up at the Symbion site…
WHEN
25th. February 2025, 08:30 – 11:00
WHERE
Symbion Frederiksberg, Nordre Fasanvej 215
WHO FOR
Anyone working on an ADC, monoclonal antibody, bispecific, or small molecule.